Table 3.

Effect of anti-TNF therapy on tumor variables, as well as body and spleen weights

Tumor weight, body weight, and spleen weightControl monoclonal antibodyAnti-TNF
Tumor diameter (mm)*9.38 ± 0.75a7.21 ± 0.64b
Tumor weight (g)*0.51 ± 0.10a0.34 ± 0.06a
Body weight (g)*26.3 ± 0.4a25.4 ± 0.4a
Spleen weight (mg/100 g body weight)*564 ± 26a492 ± 12b
Proliferation or apoptosis within mammary ducts and lobulesControl monoclonal antibodyAnti-TNF
Ducts: Ki67-positive nuclei (%)54.0 ± 2.4a48.5 ± 2.8a
Lobules: Ki67-positive nuclei (%)40.5 ± 1.6a34.9 ± 2.1b
Lesions: Ki67-positive (%)44.8 ± 1.8a45.7 ± 1.6a
Ducts: TUNEL-positive cells (%)7.7 ± 1.0a8.5 ± 1.2a
Lobules: TUNEL-positive cells (%)10.7 ± 1.0a8.6 ± 0.8a
Lesions: TUNEL-positive (%)11.1 ± 1.4a11.2 ± 1.2a
  • *Values are mean ± SE from 20 mice per group.

  • Values are mean ± SE from 10 mice per group. A total of 117 to 120 ducts, lobules, or hyperplasias/putative preneoplastic lesions were counted in each group. Means in a row without a common letter are statistically different.